Dopamine inhibits the expression of proinflammatory cytokines of microglial cells through the formation of dopamine quinone in the mouse striatum

Yoshioka, Yasuhiro; Sugino, Yuta; Yamamuro, Akiko; Ishimaru, Yuki; Maeda, Shin

doi:10.1016/j.jphs.2021.10.004

Cited by 5 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, in vitro experiments reported that L‐dopa has an inhibitory effect on microglial NO production 118 . Moreover, similar to DA, L‐dopa alone or in combination with carbidopa exerts an anti‐ inflammatory effect on microglia by forming DAQ 199 …”

Section: Immune Regulatory Effects Of Dopaminergic Antiparkinsonian D...mentioning

confidence: 97%

“…118 Moreover, similar to DA, L-dopa alone or in combination with carbidopa exerts an anti-inflammatory effect on microglia by forming DAQ. 199 L-dopa has been demonstrated to regulate immune responses in the periphery and CNS. In the periphery L-dopa reported anti-apoptotic and regulatory effects on antioxidant functions.…”

Section: Immune Regulatory Effects Of Dopaminergic Antiparkinsonian D...mentioning

confidence: 99%

“…However, chronic treatment with L‐dopa may also affect the protein expression of DRs thus potentially influencing its immune regulatory functions in PD 38,186,187 . The immune regulatory effect of L‐dopa on CNS seems to depend on the drug administration regimens and the DR‐independent mechanisms it acts through 188,199 . Thus, precisely managing L‐dopa treatment regimens may limited side‐effects while achieving neuroprotective outcomes.…”

Section: Immune Regulatory Effects Of Dopaminergic Antiparkinsonian D...mentioning

confidence: 99%

“… 118 Moreover, similar to DA, L‐dopa alone or in combination with carbidopa exerts an anti‐ inflammatory effect on microglia by forming DAQ. 199 …”

Section: Immune Regulatory Effects Of Dopaminergic Antiparkinsonian D...mentioning

confidence: 99%

See 3 more Smart Citations

Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?

Furgiuele,

Pereira,

Martini

et al. 2023

Clin & Trans Imm

View full text Add to dashboard Cite

Parkinson's disease (PD) is a neurodegenerative disease affecting 7–10 million people worldwide. Currently, there is no treatment available to prevent or delay PD progression, partially due to the limited understanding of the pathological events which lead to the death of dopaminergic neurons in the substantia nigra in the brain, which is known to be the cause of PD symptoms. The current available treatments aim at compensating dopamine (DA) deficiency in the brain using its precursor levodopa, dopaminergic agonists and some indirect dopaminergic agents. The immune system is emerging as a critical player in PD. Therefore, immune‐based approaches have recently been proposed to be used as potential antiparkinsonian agents. It has been well‐known that dopaminergic pathways play a significant role in regulating immune responses in the brain. Although dopaminergic agents are the primary antiparkinsonian treatments, their immune regulatory effect has yet to be fully understood. The present review summarises the current available evidence of the immune regulatory effects of DA and its mimics and discusses dopaminergic agents as antiparkinsonian drugs. Based on the current understanding of their involvement in the regulation of neuroinflammation in PD, we propose that targeting immune pathways involved in PD pathology could offer a better treatment outcome for PD patients.

show abstract

Section: Immune Regulatory Effects Of Dopaminergic Antiparkinsonian D...mentioning

confidence: 97%

Section: Immune Regulatory Effects Of Dopaminergic Antiparkinsonian D...mentioning

confidence: 99%

Section: Immune Regulatory Effects Of Dopaminergic Antiparkinsonian D...mentioning

confidence: 99%

“… 118 Moreover, similar to DA, L‐dopa alone or in combination with carbidopa exerts an anti‐ inflammatory effect on microglia by forming DAQ. 199 …”

Section: Immune Regulatory Effects Of Dopaminergic Antiparkinsonian D...mentioning

confidence: 99%

See 2 more Smart Citations

Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?

Furgiuele,

Pereira,

Martini

et al. 2023

Clin & Trans Imm

View full text Add to dashboard Cite

show abstract

“…In consequence, limiting the production of these inflammatory mediators is thought to be an effective treatment for inflammation pain. There is evidence that dopamine attenuated lipopolysaccharide‐induced expression of proinflammatory cytokines by inhibiting NF‐κB–p65 through the formation of dopamine quinone in microglia cells (Yoshioka et al, 2022), suggesting that dopamine or dopamine agonists can be helpful such as anti‐inflammatory and antinociceptive agents.…”

Section: Introductionmentioning

confidence: 99%

Pramipexole inhibits formalin‐induce acute and long‐lasting mechanical hypersensitivity via NF‐kB pathway in rats

Santamaria‐Anzures

Pérez‐Ramos

Mendoza‐Pérez

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

Pain is one of the most frequent causes for patients to seek medical care. It interferes with daily functioning and affects the quality of life of the patient. There is a clear need to investigate nonopioid or non-nonsteroidal anti-inflammatory drug alternatives for the treatment of pain. In this study, we determined the effect of acute pre-and posttreatment with pramipexole (PPX), a dopamine D2/D3 selective agonist, on formalin 1%-induced acute and long-lasting nociceptive behavior sensitivity in rats.Moreover, we sought to investigate whether the antiallodynic and antihyperalgesic effect induced by PPX was mediated through the nuclear factor-κB (NF-kB) signaling pathway. Moreover, acute systemic pretreatment with PPX (1 and 3 mg/kg, ip) suppressed the formalin-induced nociceptive behavior during both phases of the formalin test and the development of formalin-induced secondary mechanical allodynia and hyperalgesia in both paws. Acute systemic posttreatment with PPX (3 mg/kg, ip) reverted the formalin-induced long-lasting secondary mechanical allodynia and hyperalgesia. Furthermore, PPX inhibits the protein expression of NF-κB-p65 and the levels of tumor necrosis factor-α and interleukin-1β in the spinal cord of animals with secondary mechanical allodynia and hyperalgesia induced by formalin. These data suggest that PPX has a potential role in producing anti-inflammatory activity.Moreover, the antiallodynic and antihyperalgesic effects induced by PPX can be mediated through the NF-kB signaling pathway.

show abstract

Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study

Khrieba,

Hegazy,

Mustafa

et al. 2024

Inflammopharmacol

View full text Add to dashboard Cite

Dopamine inhibits the expression of proinflammatory cytokines of microglial cells through the formation of dopamine quinone in the mouse striatum

Cited by 5 publications

References 37 publications

Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?

Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?

Pramipexole inhibits formalin‐induce acute and long‐lasting mechanical hypersensitivity via NF‐kB pathway in rats

Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study

Contact Info

Product

Resources

About